Drug Giant Roche Offers $5.7 Billion For Illumina
The business of using genetic codes and mapping to cure human health problems has taken a new turn. Roche offered to buy DNA map firm Illumina for a premium of over 60%–$5.7 billion. Illimina and Affimetix are the leaders in their…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The business of using genetic codes and mapping to cure human health problems has taken a new turn. Roche offered to buy DNA map firm Illumina for a premium of over 60%–$5.7 billion.
Illimina and Affimetix are the leaders in their field, and have taken years to create their products. Roche must believe it is better to buy than build in a world in which medical tech advances by the day
Contact [email protected] for any questions or corrections.


